- Home
- GOSS vs REPL Comparison
GOSS vs REPL Comparison
Compare GOSS & REPL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GOSS
- REPL
- Stock Information
- Founded
- GOSS 2015
- REPL 2015
- Country
- GOSS United States
- REPL United States
- Employees
- GOSS N/A
- REPL N/A
- Industry
- GOSS Biotechnology: Pharmaceutical Preparations
- REPL Biotechnology: Pharmaceutical Preparations
- Sector
- GOSS Health Care
- REPL Health Care
- Exchange
- GOSS Nasdaq
- REPL Nasdaq
- Market Cap
- GOSS 585.9M
- REPL 547.0M
- IPO Year
- GOSS 2019
- REPL 2018
- Fundamental
- Price
- GOSS $2.41
- REPL $4.74
- Analyst Decision
- GOSS Strong Buy
- REPL Hold
- Analyst Count
- GOSS 6
- REPL 9
- Target Price
- GOSS $8.60
- REPL $6.67
- AVG Volume (30 Days)
- GOSS 3.7M
- REPL 5.0M
- Earning Date
- GOSS 11-06-2025
- REPL 11-11-2025
- Dividend Yield
- GOSS N/A
- REPL N/A
- EPS Growth
- GOSS N/A
- REPL N/A
- EPS
- GOSS N/A
- REPL N/A
- Revenue
- GOSS $40,237,000.00
- REPL N/A
- Revenue This Year
- GOSS N/A
- REPL N/A
- Revenue Next Year
- GOSS $34.10
- REPL N/A
- P/E Ratio
- GOSS N/A
- REPL N/A
- Revenue Growth
- GOSS N/A
- REPL N/A
- 52 Week Low
- GOSS $0.66
- REPL $2.68
- 52 Week High
- GOSS $3.60
- REPL $17.00
- Technical
- Relative Strength Index (RSI)
- GOSS 44.51
- REPL 48.42
- Support Level
- GOSS $2.25
- REPL $4.30
- Resistance Level
- GOSS $2.61
- REPL $4.95
- Average True Range (ATR)
- GOSS 0.18
- REPL 0.27
- MACD
- GOSS -0.05
- REPL 0.08
- Stochastic Oscillator
- GOSS 24.58
- REPL 68.27
About GOSS Gossamer Bio Inc.
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.
About REPL Replimune Group Inc.
Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3. The company operates in USA and UK, majority of revenue from USA.